Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex

Molecular Cancer Therapeutics

Volumn 13, Issue 7, 2014, Pages 1803-1812

  Cheal, Sarah M ^a   Xu, Hong ^a   Guo, Hong Fen ^a   Zanzonico, Pat B ^a   Larson, Steven M ^a   Cheung, Nai Kong ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; GANGLIOSIDE GD2; HU3F8 C825 I 124; IMMUNOGLOBULIN G; LUTETIUM 177; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STREPTAVIDIN; TETRAXETAN BN LU 177; UNCLASSIFIED DRUG; YTTRIUM 90; GANGLIOSIDE; GANGLIOSIDE, GD2; IMMUNOGLOBULIN FRAGMENT; LUTETIUM; OCTREOTIDE; ORGANOMETALLIC COMPOUND; YTTRIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG STABILITY; DRUG UPTAKE; EVALUATION STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; ISOTOPE LABELING; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; RADIATION EXPOSURE; THERAPY EFFECT; TUMOR ABLATION; TUMOR RECURRENCE; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG SCREENING; IMMUNOLOGY; NUDE MOUSE; RADIOIMMUNOTHERAPY; RANDOMIZATION;

ANIMALS; ANTIBODIES, BISPECIFIC; DRUG EVALUATION, PRECLINICAL; FEMALE; GANGLIOSIDES; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN G; LUTETIUM; MICE; MICE, NUDE; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTRIUM RADIOISOTOPES;

EID: 84904174507     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0933     Document Type: Article

References (30)

1. Cheung NKV, Modak S, Lin YK, Guo HF, Zanzonico P, Chung J, et al. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. J Nucl Med 2004;45:867-77. (Pubitemid 47618568)
2. Sharkey RM, Goldenberg DM. Cancer radioimmunotherapy. Immunotherapy 2011;3:349-70.
3. Reardan DT, Meares CF, Goodwin DA, McTigue M, David GS, Stone MR, et al. Antibodies against metal chelates. Nature 1985;316:265-8. (Pubitemid 15073694)
4. Goodwin DA, Meares CF, Watanabe N, McTigue M, Chaovapong W, Ransone CM, et al. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy. Cancer Res 1994;54:5937-46.
5. Orcutt KD, Slusarczyk AL, Cieslewicz M, Ruiz-Yi B, Bhushan KR, Frangioni JV, et al. Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. Nucl Med Biol 2011;38:223-33.
6. Orcutt KD, Ackerman ME, Cieslewicz M, Quiroz E, Slusarczyk AL, Frangioni JV, et al. A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel 2010;23:221-8.
7. Orcutt KD, Rhoden JJ, Ruiz-Yi B, Frangioni JV, Wittrup KD. Effect of small-molecule-binding affinity on tumor uptake in vivo: a systematic study using a pretargeted bispecific antibody. Mol Cancer Ther 2012;11:1365-72.
8. Cheung NK, Guo H, Hu J, Tassev DV, Cheung IY. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology 2012;1:477-86.
9. Orcutt KD, Nasr KA, Whitehead DG, Frangioni JV, Wittrup KD. Biodistribution and clearance of small-molecule hapten chelates for pretargeted radioimmunotherapy. Mol Imaging Biol 2011;13:215-21.
10. Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO, et al. Ganglioside GD2 identi fies breast cancer stem cells and promotes tumorigenesis. J Clin Invest 2012;122:2066-78.
11. Ponomarev V, Doubrovin M, Serganova I, Vider J, Shavrin A, Beresten T, et al. A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging 2004;31:740-51. (Pubitemid 38647915)
12. Corneillie TM, Whetstone PA, Fisher AJ, Meares CF. A rare earth-DOTA-binding antibody: probe properties and binding affi nity across the lanthanide series. J Am Chem Soc 2003;125:3436-7. (Pubitemid 36512411)
13. Hermanson GT. Bioconjugate techniques. 2nd ed. London: Academic Press; 2008.
14. Hu J, Huang X, Ling CC, Bundle DR, Cheung NK. Reducing epitope spread during affinity maturation of an anti-ganglioside GD2 antibody. J Immunol 2009;183:5748-55.
15. Harlow E, Lane D. Using antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1999.
16. Salacinski PR, McLean C, Sykes JE, Clement-Jones VV, Lowry PJ. Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenyl glycoluril (Iodogen). Anal Biochem 1981;117:136-46. (Pubitemid 12211794)
17. Miederer M, McDevitt MR, Sgouros G, Kramer K, Cheung NK, Scheinberg DA. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J Nucl Med 2004;45:129-37. (Pubitemid 47611619)
18. Cheung NK, Landmeier B, Neely J, Nelson AD, Abramowsky C, Ellery S, et al. Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-speci fic monoclonal antibody against human neuroblastoma xenografted in nude mice. J Natl Cancer Inst 1986;77:739-45. (Pubitemid 16016593)
19. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 2010;51:1293-300.
20. Ugur O, Kostakoglu L, Hui ET, Fisher DR, Garmestani K, Gansow OA, et al. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses. Nucl Med Biol 1996;23:1-8. (Pubitemid 26053202)
21. Press OW, Corcoran M, Subbiah K, Hamlin DK, Wilbur DS, Johnson T, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 2001;98:2535-43.
22. Sharkey RM, Karacay H, Chang CH, McBride WJ, Horak ID, Goldenberg DM. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia 2005;19:1064-9. (Pubitemid 40862020)
23. Frampas E, Maurel C, Remaud-Le Saec P, Mauxion T, Faivre-Chauvet A, Davodeau F, et al. Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide. Eur J Nucl Med Mol Imaging 2011;38:2153-64.
24. Russell J, Wheldon TE, Stanton P. A radioresistant variant derived from a human neuroblastoma cell line is less prone to radiation-induced apoptosis. Cancer Res 1995;55:4915-21.
25. O'Donoghue J. Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy. Cancer Biother Radiopharm 2004;19:378-87. (Pubitemid 38924504)
26. Liu G, Hnatowich DJ. A semiempirical model of tumor pretargeting. Bioconjug Chem 2008;19:2095-104.
27. Graff CP, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res 2003;63:1288-96. (Pubitemid 36348707)
28. Yazaki PJ, Lee B, Channappa D, Cheung CW, Crow D, Chea J, et al. A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Eng Des Sel 2013;26:187-93.
29. Zhao Q, Feng Y, Zhu Z, Dimitrov DS. Human monoclonal antibody fragments binding to insulin-like growth factors I and II with picomolar affinity. Mol Cancer Ther 2011;10:1677-85.
30. Corneillie TM, Whetstone PA, Lee KC, Wong JP, Meares CF. Converting weak binders into infinite binders. Bioconjug Chem 2004;15:1389-91. (Pubitemid 39552029)